NRD
FATE icon

Nebula Research & Development’s Fate Therapeutics FATE Stock Holding History

Nebula Research & Development’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-46,631
Closed -$163K – 969
2024
Q3 		$163K Sell
46,631
-11,734
-20% -$45.7K 0.02% 849
2024
Q2 		$191K Buy
+58,365
New +$255K 0.03% 732
2023
Q4 		– Sell
-163,617
Closed -$347K – 719
2023
Q3 		$347K Buy
163,617
+121,025
+284% +$401K 0.18% 231
2023
Q2 		$203K Buy
+42,592
New +$235K 0.15% 271

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Nebula Research & Development's FATE Position: Q4 2024 in Review

Nebula Research & Development sold out of Fate Therapeutics (FATE) in Q4 2024, closing a stake of 46,631 shares — an estimated $163K sold.

Nebula Research & Development first reported a position in FATE in Q2 2023 and held it in 4 quarters. The position peaked at $347K in Q3 2023. 159 funds tracked by Wall St. Rank hold FATE as of Q4 2024.

  • Nebula Research & Development reported no remaining Fate Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Nebula Research & Development sold 46,631 Fate Therapeutics shares in Q4 2024, an estimated $163K.
  • Nebula Research & Development first reported a position in Fate Therapeutics in Q2 2023 and held it in 4 quarters.
  • Nebula Research & Development's Fate Therapeutics position peaked at $347K in Q3 2023.
  • 159 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2024.

Based on Nebula Research & Development's 13F filing for Q4 2024, filed 14 Feb 2025.